Accelerate performance with advanced technologies that deliver faster scale-up, greater control and consistent, high-quality outcomes.
PHT Pharma’s technology platforms are designed to support pharmaceutical partners with high-precision, scalable and compliant development capabilities. Our advanced chemistry and engineering technologies enable efficient synthesis, rapid scale-up, safe process implementation and seamless commercial transfer. With a sustained focus on quality, sustainability and regulatory readiness, our technology infrastructure ensures consistent performance across early-stage research to through full-scale production.
By combining innovation with disciplined execution, PHT Pharma delivers robust, reproducible and commercially viable outcomes that accelerate time-to-market while meeting stringent cGMP and global regulatory standards.
Our small-molecule CDMO platform integrates route design, process development, scale-up, and cGMP manufacture to support programs from milligram discovery quantities through kilogram clinical supply to multi-ton commercial production. We specialize in complex RSMs and key intermediates, pairing deep synthetic chemistry with robust process engineering to deliver reliable, compliant supply across the product lifecycle.
In early development, we provide rapid route scouting and feasibility assessment, using DoE principles to identify scalable, cost-effective pathways. Capabilities include multistep synthesis, heterocycle construction, chiral synthesis (asymmetric and resolution), and metal-catalysed transformations, with workups and isolations designed for manufacturability.
We also offer hydrogenation in flow and batch, from catalyst screening and selectivity optimisation through pressure-rated scale-up, with a focus on safety, control, and impurity minimization.
Our approach to process development is driven by DoE-led optimization, reaction calorimetry/hazard assessment, and impurity pathway mapping, including control strategies for process-related and potentially genotoxic impurities. Solid-form support includes salt/polymorph screening, crystallisation development, particle-size control, and drying/residual-solvent management. For late-phase and commercial manufacture, we apply a Quality-by-Design (“QbD”) approach, define proven acceptable ranges, and execute validation and continued process verification, supported by dedicated analytical chemistry development (methods, stability, and lifecycle management).
Flow chemistry can accelerate chemical development and de‑risk manufacturing by running reactions in a continuously fed, well‑controlled reactor rather than a large batch vessel. Enhanced heat and mass transfer enables tighter temperature control, rapid mixing and precise residence‑time tuning, which often improves selectivity and reduces impurity formation. Safety is a major advantage: hazardous chemistries (highly exothermic steps, diazomethane/azides, nitrations, gas–liquid hydrogenations) can be performed with small in‑process inventories and efficient heat removal, lowering runaway and exposure risk. Development is faster because conditions can be screened and optimized quickly, then scaled by increasing runtime (“scale‑out”) or reactor numbering‑up, avoiding many scale‑up surprises. Inline analytics (PAT) and automated control support real‑time quality assurance and consistent product output. Continuous work‑up or telescoped multistep sequences can cut solvent use, isolate fewer intermediates, shorten cycle times and reduce cost of goods, delivering robust, sustainable routes from lab to plant.
Robust quality systems are the backbone of a high performing CDMO, ensuring every project is executed consistently, traceably and in full compliance. Our Quality System, which is based on ICH-Q7 guidelines, integrates document control, training, deviation/OOS investigations, CAPA and disciplined change control to protect product quality and maintain inspection readiness. Validation provides objective evidence that processes, analytical methods, cleaning and computerized systems perform as intended, supporting scale up from clinical batches to commercial manufacture through PPQ and continued process verification. A strong data integrity program, aligned with ALCOA+ principles, safeguards raw data and audit trails via secure access, contemporaneous recording and lifecycle retention, making batch release decisions and regulatory submissions defensible. Finally, regulatory alignment with ICH and global GMP expectations is embedded into daily practice through risk based quality management, supplier oversight and clear quality agreements, so our customers receive compliant materials, audit ready documentation and dependable supply from development through to commercial launch, with metrics and continuous improvement at each stage.